We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Mednax (MD) Up 46.5% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Mednax (MD - Free Report) . Shares have added about 46.5% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Mednax due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
MEDNAX's Earnings Miss Estimates in Q1, Tumble Y/Y
MEDNAX reported first-quarter 2020 adjusted earnings of 32 cents per share, missing the Zacks Consensus Estimate by 23.8%. Moreover, the bottom line plunged 50.8% year over year.
The company’s results were negatively impacted by the COVID-19 pandemic. In fact, the coronavirus outbreak dented patient volumes as well as revenue.
Quarterly Details
The company generated revenues of $846 million, which missed the Zacks Consensus Estimate by 0.6%. Also, the top line slid 0.6% from the year-ago period.
Same unit revenues dipped 1% year over year.
General and administrative expenses inched 3.3% to $105.2 million. Interest expense of the company declined 10.1% to $27.6 million on the back of lower borrowings.
In the quarter under review, EBITDA totaled $63.4 million, down 39.6% year over year.
The company invested $13.7 million in capital expenditures. Withdrawal of Preliminary Outlook
Given the current pandemic-led uncertainty, the company scrapped its previously-announced quarterly and 2020 outlook.
Financial Update
As of Mar 31, 2020, the company had cash and cash equivalents of $312 million, up 177% from the level at 2019 end.
The company’s total debt of $2.1 billion was up 21.5% from the level at 2019 end while total assets worth $4.3 billion rose 4.2% from the level at 2019 end.
Cash flow used in operating activities was $146.4 million in the quarter under review, jumping 142.4% year over year.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month. The consensus estimate has shifted -25.34% due to these changes.
VGM Scores
At this time, Mednax has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Mednax has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Mednax (MD) Up 46.5% Since Last Earnings Report?
A month has gone by since the last earnings report for Mednax (MD - Free Report) . Shares have added about 46.5% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Mednax due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
MEDNAX's Earnings Miss Estimates in Q1, Tumble Y/Y
MEDNAX reported first-quarter 2020 adjusted earnings of 32 cents per share, missing the Zacks Consensus Estimate by 23.8%. Moreover, the bottom line plunged 50.8% year over year.
The company’s results were negatively impacted by the COVID-19 pandemic. In fact, the coronavirus outbreak dented patient volumes as well as revenue.
Quarterly Details
The company generated revenues of $846 million, which missed the Zacks Consensus Estimate by 0.6%. Also, the top line slid 0.6% from the year-ago period.
Same unit revenues dipped 1% year over year.
General and administrative expenses inched 3.3% to $105.2 million.
Interest expense of the company declined 10.1% to $27.6 million on the back of lower borrowings.
In the quarter under review, EBITDA totaled $63.4 million, down 39.6% year over year.
The company invested $13.7 million in capital expenditures.
Withdrawal of Preliminary Outlook
Given the current pandemic-led uncertainty, the company scrapped its previously-announced quarterly and 2020 outlook.
Financial Update
As of Mar 31, 2020, the company had cash and cash equivalents of $312 million, up 177% from the level at 2019 end.
The company’s total debt of $2.1 billion was up 21.5% from the level at 2019 end while total assets worth $4.3 billion rose 4.2% from the level at 2019 end.
Cash flow used in operating activities was $146.4 million in the quarter under review, jumping 142.4% year over year.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month. The consensus estimate has shifted -25.34% due to these changes.
VGM Scores
At this time, Mednax has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Mednax has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.